Gain Therapeutics, Inc.(GANX)Earnings, Financials & Key Ratios
GANX•NASDAQ
$1.91
$69M mkt cap·Price updated May 6, 2026
AboutGain Therapeutics, Inc., a biotechnology company, engages in developing various therapies to treat diseases caused by protein misfolding. It focuses on rare genetic diseases and neurological disorders. The company uses its Site-Directed Enzyme Enhancement Therapy platform to discover allosteric sites on misfolded proteins and identify proprietary small molecules that bind these sites, restore protein folding, and treat disease. It is developing structurally targeted allosteric regulator candidates to treat various diseases, including Morquio B, GM1 gangliosidosis (GM1), neuronopathic Gaucher disease, GBA1 Parkinson's, Krabbe, and Mucopolysaccharidosis type 1 diseases. The company was founded in 2017 and is based in Bethesda, Maryland.Show more
- Revenue$0-100.0%
- EBITDA-$20M+8.6%
- Net Income-$20M+8.3%
- EPS (Diluted)-0.89+48.0%
- ROE-204.95%-44.8%
- Debt/Equity0.09+8.9%
GANX Key Insights
Gain Therapeutics, Inc. (GANX) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
✗Weaknesses
- ✗Weak Piotroski F-Score: 2/9
- ✗Weak momentum: RS Rating 19 (bottom 19%)
- ✗Shares diluted 75.9% in last year
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
GANX Price & Volume
Gain Therapeutics, Inc. (GANX) stock price & volume — 10-year historical chart
Loading chart...
GANX Growth Metrics
Gain Therapeutics, Inc. (GANX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM9.24%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM41.73%
Return on Capital
10 Years-1095.98%
5 Years-108.02%
3 Years-127.15%
Last Year-186.09%
GANX Recent Earnings
Gain Therapeutics, Inc. (GANX) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 5/12 qtrs (42%)●Beat Revenue 2/12 qtrs (67%)
Q4 2025Latest
Nov 12, 2025EPS
$0.15
Est $0.15
+0.0%
Revenue
—
Q3 2025
Aug 12, 2025EPS
$0.19
Est $0.17
-11.8%
Revenue
—
Q2 2025
May 14, 2025EPS
$0.16
Est $0.16
+0.0%
Revenue
—
Est $25,000
Q2 2025
Mar 27, 2025EPS
$0.11
Est $0.18
+38.9%
Revenue
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q4 2025Latest | Nov 12, 2025 | $0.15vs $0.15+0.0% | — |
| Q3 2025 | Aug 12, 2025 | $0.19vs $0.17-11.8% | — |
| Q2 2025 | May 14, 2025 | $0.16vs $0.16+0.0% | —vs $25,000 |
| Q2 2025 | Mar 27, 2025 | $0.11vs $0.18+38.9% | — |
Based on last 12 quarters of dataView full earnings history →
GANX Peer Comparison
Gain Therapeutics, Inc. (GANX) competitors in Neuroscience and Psychiatry Therapies — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 PRAX | 7.61B | 337.95 | -25.07 | -100% | -58.74% | 0.00 | ||
 ACMR | 3.67B | 55.38 | 40.42 | 15.24% | 10.44% | 6.11% | 0.16 | |
 RARE | 2.55B | 25.93 | -4.45 | 20.13% | -91.03% | -6.08% | ||
 FOLD | 4.47B | 14.49 | -80.50 | 32.29% | -2.35% | -6.1% | 2.29 | |
 LGND | 4.57B | 232.55 | -1057.05 | 27.28% | 19.34% | 5.11% | 0.01 | |
 NTLA | 1.61B | 13.85 | -3.64 | -100% | -61.47% | 0.14 | ||
 BEAM | 3.32B | 32.33 | -39.92 | 120.01% | -57.24% | -7.31% | 0.24 | |
 CRSP | 5.31B | 55.08 | -8.51 | -89.97% | -138.57% | -30.88% | 0.21 |
Compare GANX vs Peers
Gain Therapeutics, Inc. (GANX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
GANX Income Statement
Gain Therapeutics, Inc. (GANX) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 20.61K | 41.3K | 28.88K | 133.93K | 132.64K | 55.18K | 0 | 0 |
| Revenue Growth % | - | 100.4% | -30.07% | 363.72% | -0.96% | -58.4% | -100% | - |
| Cost of Goods Sold | 0 | 0 | 0 | 7.16M | 8.24M | 0 | 0 | 4.99M |
| COGS % of Revenue | - | - | - | 5349.31% | 6214.63% | - | - | - |
| Gross Profit | 0▲ 0% | 41.3K▲ 0% | 28.88K▼ 30.1% | -7.03M▼ 24442.3% | -8.11M▼ 15.4% | 55.18K▲ 100.7% | 0▼ 100.0% | -4.99M▲ 0% |
| Gross Margin % | - | 100% | 100% | -5249.31% | -6114.63% | 100% | - | - |
| Gross Profit Growth % | - | - | -30.07% | -24442.3% | -15.36% | 100.68% | -100% | - |
| Operating Expenses | 1.05M | 2.14M | 3.51M | 6.8M | 9.67M | 22.31M | 20.35M | 12.59M |
| OpEx % of Revenue | 5089.65% | 5184.89% | 12147.54% | 5074.27% | 7287.85% | 40428.26% | - | - |
| Selling, General & Admin | 222.05K | 555.16K | 1.25M | 6.84M | 9.68M | 10.79M | 9.56M | 8.54M |
| SG&A % of Revenue | 1077.43% | 1344.19% | 4325.08% | 5105.93% | 7301.18% | 19550.02% | - | - |
| Research & Development | 826.88K | 1.59M | 2.26M | 7.35M | 8.46M | 11.52M | 10.79M | 9.79M |
| R&D % of Revenue | 4012.23% | 3840.69% | 7822.46% | 5487.26% | 6377.73% | 20878.24% | - | - |
| Other Operating Expenses | 0 | 0 | 0 | -7.39M | -8.48M | 0 | 0 | -2M |
| Operating Income | -1.03M▲ 0% | -2.1M▼ 104.2% | -3.48M▼ 65.7% | -13.83M▼ 297.4% | -17.78M▼ 28.6% | -22.25M▼ 25.2% | -20.35M▲ 8.5% | -17.58M▲ 0% |
| Operating Margin % | -4989.65% | -5084.89% | -12047.54% | -10323.59% | -13402.48% | -40328.26% | - | - |
| Operating Income Growth % | - | -104.23% | -65.68% | -297.37% | -28.58% | -25.18% | 8.55% | - |
| EBITDA | -1.03M | -2.1M | -3.47M | -13.81M | -17.75M | -22.17M | -20.27M | -17.51M |
| EBITDA Margin % | -4986.06% | -5078.66% | -12014.32% | -10312.03% | -13382.4% | -40176.79% | - | - |
| EBITDA Growth % | - | -104.12% | -65.43% | -298.02% | -28.53% | -24.9% | 8.58% | 18.07% |
| D&A (Non-Cash Add-back) | 741 | 2.57K | 9.59K | 15.48K | 26.63K | 83.58K | 84.07K | 63.11K |
| EBIT | -1.03M | -2.1M | -3.48M | -13.84M | -17.79M | -22.25M | -20.35M | -17.47M |
| Net Interest Income | -52.48K | -20.54K | 3.64K | 12.49K | 375.36K | 494.23K | 357.1K | 212.91K |
| Interest Income | 0 | 0 | 3.64K | 12.49K | 375.36K | 494.23K | 357.1K | 212.91K |
| Interest Expense | 52.48K | 20.54K | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Income/Expense | -67.44K | -86.22K | -92.85K | -60.42K | 279.28K | 64.89K | 476.22K | -520.22K |
| Pretax Income | -1.1M▲ 0% | -2.19M▼ 99.5% | -3.57M▼ 63.4% | -13.89M▼ 288.7% | -17.5M▼ 26.0% | -22.19M▼ 26.8% | -19.87M▲ 10.4% | -18.1M▲ 0% |
| Pretax Margin % | -5316.9% | -5293.65% | -12369.02% | -10368.7% | -13191.92% | -40210.67% | - | - |
| Income Tax | 9.78K | 7.11K | 5.39K | 4.01K | 92.98K | 79.28K | 536.82K | 1.3M |
| Effective Tax Rate % | -0.89% | -0.33% | -0.15% | -0.03% | -0.53% | -0.36% | -2.7% | -7.16% |
| Net Income | -1.11M▲ 0% | -2.19M▼ 98.4% | -3.58M▼ 63.1% | -13.89M▼ 288.3% | -17.59M▼ 26.6% | -22.27M▼ 26.6% | -20.41M▲ 8.3% | -19.39M▲ 0% |
| Net Margin % | -5364.36% | -5310.88% | -12387.67% | -10371.7% | -13262.02% | -40354.33% | - | - |
| Net Income Growth % | - | -98.4% | -63.11% | -288.26% | -26.64% | -26.59% | 8.34% | 9.24% |
| Net Income (Continuing) | -1.11M | -2.19M | -3.58M | -13.89M | -17.59M | -22.27M | -20.41M | -19.39M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.19▲ 0% | -0.26▼ 36.8% | -0.30▼ 15.4% | -1.37▼ 356.7% | -1.48▼ 8.0% | -1.71▼ 15.5% | -0.89▲ 48.0% | -0.55▲ 0% |
| EPS Growth % | - | -36.84% | -15.38% | -356.67% | -8.03% | -15.54% | 47.95% | 41.73% |
| EPS (Basic) | -0.19 | -0.37 | -0.30 | -1.37 | -1.48 | -1.71 | -0.89 | - |
| Diluted Shares Outstanding | 5.86M | 8.37M | 11.88M | 10.17M | 11.88M | 13.01M | 22.88M | 35M |
| Basic Shares Outstanding | 5.86M | 8.37M | 11.88M | 10.17M | 11.88M | 13.01M | 22.88M | 35M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - |
GANX Balance Sheet
Gain Therapeutics, Inc. (GANX) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 494.64K | 398.05K | 8.99M | 37.72M | 21.09M | 17.78M | 11.6M | 10.52M |
| Cash & Short-Term Investments | 400.69K | 303.32K | 7.49M | 36.88M | 20.14M | 16.79M | 10.39M | 8.81M |
| Cash Only | 400.69K | 303.32K | 7.49M | 36.88M | 7.31M | 11.79M | 10.39M | 8.81M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 12.83M | 5M | 0 | 0 |
| Accounts Receivable | 0 | 44.91K | 8.55K | 195.45K | 103.88K | 242.58K | 765.76K | 0 |
| Days Sales Outstanding | - | 396.94 | 108.03 | 532.66 | 285.85 | 1.6K | - | - |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - |
| Other Current Assets | 93.94K | 0 | 1.29M | 0 | 640.31K | 0 | 369.89K | 1.71M |
| Total Non-Current Assets | 317K | 262.24K | 616.53K | 1.26M | 3.01M | 830.46K | 521.41K | 454.41K |
| Property, Plant & Equipment | 305.79K | 219.35K | 552.71K | 1.01M | 804.31K | 585.18K | 323.33K | 269.99K |
| Fixed Asset Turnover | 0.07x | 0.19x | 0.05x | 0.13x | 0.16x | 0.09x | - | 0.00x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 202.61K | 213.97K | 193.38K | 134.27K | 0 |
| Long-Term Investments | 0 | 10.38K | 0 | 31.28K | 1.94M | 0 | 31.7K | 31.7K |
| Other Non-Current Assets | 11.21K | 32.51K | 63.82K | 53.39K | 48.32K | 51.91K | 32.11K | 351.74K |
| Total Assets | 811.63K▲ 0% | 660.29K▼ 18.6% | 9.6M▲ 1354.6% | 38.99M▲ 305.9% | 24.1M▼ 38.2% | 18.61M▼ 22.8% | 12.12M▼ 34.9% | 10.97M▲ 0% |
| Asset Turnover | 0.03x | 0.06x | 0.00x | 0.00x | 0.01x | 0.00x | - | 0.00x |
| Asset Growth % | - | -18.65% | 1354.58% | 305.91% | -38.18% | -22.78% | -34.85% | -127.51% |
| Total Current Liabilities | 530.79K | 879.05K | 2.11M | 2.55M | 4.13M | 4.95M | 3.91M | 4.17M |
| Accounts Payable | 149.33K | 154.44K | 961.52K | 560.48K | 1.63M | 1.32M | 946.26K | 1.58M |
| Days Payables Outstanding | - | - | - | 28.55 | 72 | - | - | 135.11 |
| Short-Term Debt | 0 | 102.11K | 22.63K | 103.83K | 108.14K | 118.8K | 110.18K | 115.91K |
| Deferred Revenue (Current) | 0 | 368.8K | 0 | 266.5K | 55.18K | 1.12M | 252.21K | 263.5K |
| Other Current Liabilities | 159.51K | 250K | 245.86K | 380 | 364.11K | 1.38M | 18.49K | 2.47M |
| Current Ratio | 0.93x | 0.45x | 4.25x | 14.78x | 5.11x | 3.59x | 2.97x | 2.97x |
| Quick Ratio | 0.93x | 0.45x | 4.25x | 14.78x | 5.11x | 3.59x | 2.97x | 2.97x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 1.23M | 231.09K | 1.29M | 1.61M | 1.09M | 1.08M | 872.99K | 891.65K |
| Long-Term Debt | 1.01M | 0 | 715.66K | 590.47K | 495.26K | 449.05K | 328.33K | 65.03K |
| Capital Lease Obligations | 200.95K | 98.84K | 400.32K | 695.05K | 441.78K | 229.85K | 53.6K | 177.04K |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 23.98K | 132.25K | 171.56K | 329.46K | 157.58K | 307.45K | 443.62K | 2.26M |
| Total Liabilities | 1.76M | 1.11M | 3.4M | 4.17M | 5.22M | 6.03M | 4.78M | 5.06M |
| Total Debt | 1.31M | 200.95K | 1.26M | 1.61M | 1.27M | 1.03M | 653.01K | 180.94K |
| Net Debt | 807.08K | -102.37K | -6.23M | -35.27M | -6.04M | -10.77M | -9.73M | -8.63M |
| Debt / Equity | - | - | 0.20x | 0.05x | 0.07x | 0.08x | 0.09x | 0.09x |
| Debt / EBITDA | - | - | - | - | - | - | - | -0.01x |
| Net Debt / EBITDA | - | - | - | - | - | - | - | 0.49x |
| Interest Coverage | -19.60x | -102.24x | - | - | - | - | - | - |
| Total Equity | -950.91K▲ 0% | -449.86K▲ 52.7% | 6.2M▲ 1478.7% | 34.82M▲ 461.4% | 18.88M▼ 45.8% | 12.58M▼ 33.4% | 7.34M▼ 41.6% | 5.91M▲ 0% |
| Equity Growth % | - | 52.69% | 1478.66% | 461.39% | -45.78% | -33.38% | -41.65% | -177.08% |
| Book Value per Share | -0.16 | -0.05 | 0.52 | 3.43 | 1.59 | 0.97 | 0.32 | 0.17 |
| Total Shareholders' Equity | -950.91K | -449.86K | 6.2M | 34.82M | 18.88M | 12.58M | 7.34M | 5.91M |
| Common Stock | 225 | 225 | 354 | 1.19K | 1.19K | 1.62K | 2.71K | 3.6K |
| Retained Earnings | -1.26M | -3.46M | -7.03M | -20.93M | -38.52M | -60.78M | -81.19M | -81.19M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 3.08K | -81.16K | -152.7K | -90.64K | 35.63K | 247.24K | -247.55K | 563.22K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
GANX Cash Flow Statement
Gain Therapeutics, Inc. (GANX) cash flow — operating, investing & free cash flow history
| Line item | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -744.51K | -1.87M | -3.24M | -12.37M | -14.69M | -18.87M | -18.87M | -18.87M |
| Operating CF Margin % | -3612.57% | -4524.13% | -11219.27% | -9233.07% | -11076.7% | -34189.69% | - | - |
| Operating CF Growth % | - | -150.97% | -73.41% | -281.63% | -18.81% | -28.41% | -0.04% | 62.76% |
| Net Income | -1.11M | -2.19M | -3.58M | -13.89M | -17.59M | -22.27M | -20.41M | -19.39M |
| Depreciation & Amortization | 741 | 2.57K | 9.59K | 15.48K | 64.17K | 83.58K | 84.07K | 87.11K |
| Stock-Based Compensation | 0 | 0 | 81.64K | 839.37K | 1.53M | 3.26M | 2.39M | 1.76M |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 41.05K | 10.1K | 8.71K | 999.87K | -206.86K | -383.19K | 143.52K | 1.35M |
| Working Capital Changes | 319.23K | 312.26K | 237.5K | -329.78K | 1.51M | 442.23K | -1.08M | -1.11M |
| Change in Receivables | 0 | -8.35K | -21.65K | -63.35K | 3.63K | 0 | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 117.69K | 5.11K | 395.54K | -521.39K | 1.07M | -643.16K | 274.89K | 258.58K |
| Cash from Investing | -7.99K | -13.72K | -20.83K | -94.21K | -14.77M | 10.22M | 4.98M | -43.45K |
| Capital Expenditures | -7.99K | -13.72K | -20.83K | -94.21K | -118.95K | -15.36K | -22.49K | -945 |
| CapEx % of Revenue | 38.75% | 33.23% | 72.11% | 70.35% | 89.68% | 27.83% | - | - |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash from Financing | 983.78K | 1.75M | 10.49M | 41.77M | -78.77K | 12.64M | 13.01M | 14.21M |
| Debt Issued (Net) | 983.78K | 0 | 738.28K | -21.95K | -78.77K | -89.07K | -90.88K | -94.26K |
| Equity Issued (Net) | 0 | 1000K | 1000K | 1000K | 0 | 1000K | 1000K | 4M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 0 | 0 | -470.75K | -841.27K | 0 | 0 | -109.36K | -353.73K |
| Net Change in Cash | 237.88K▲ 0% | -97.19K▼ 140.9% | 7.19M▲ 7498.6% | 29.41M▲ 309.0% | -29.57M▼ 200.6% | 4.49M▲ 115.2% | -1.41M▼ 131.5% | -3.24M▲ 0% |
| Free Cash Flow | -752.5K▲ 0% | -1.88M▼ 150.1% | -3.26M▼ 73.3% | -12.46M▼ 282.1% | -14.81M▼ 18.9% | -18.88M▼ 27.5% | -18.9M▼ 0.1% | -17.3M▲ 0% |
| FCF Margin % | -3651.32% | -4557.35% | -11291.38% | -9303.42% | -11166.38% | -34217.53% | - | - |
| FCF Growth % | - | -150.13% | -73.26% | -282.08% | -18.87% | -27.48% | -0.08% | 18% |
| FCF per Share | -0.13 | -0.22 | -0.27 | -1.23 | -1.25 | -1.45 | -0.83 | -0.83 |
| FCF Conversion (FCF/Net Income) | 0.67x | 0.85x | 0.91x | 0.89x | 0.84x | 0.85x | 0.92x | 0.89x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 9.44K | 4.57K | 4.47K | 2.74K | 134.96K | 86.31K | 0 |
GANX Key Ratios
Gain Therapeutics, Inc. (GANX) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM |
|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | - | -124.39% | -67.73% | -65.52% | -141.57% | -204.95% | -328.15% |
| Return on Invested Capital (ROIC) | - | - | - | -215.26% | -227.8% | - | 521.47% |
| Gross Margin | 100% | 100% | -5249.31% | -6114.63% | 100% | - | - |
| Net Margin | -5310.88% | -12387.67% | -10371.7% | -13262.02% | -40354.33% | - | - |
| Debt / Equity | - | 0.20x | 0.05x | 0.07x | 0.08x | 0.09x | 0.09x |
| Interest Coverage | -102.24x | - | - | - | - | - | - |
| FCF Conversion | 0.85x | 0.91x | 0.89x | 0.84x | 0.85x | 0.92x | 0.89x |
| Revenue Growth | 100.4% | -30.07% | 363.72% | -0.96% | -58.4% | -100% | - |
GANX Frequently Asked Questions
Gain Therapeutics, Inc. (GANX) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Gain Therapeutics, Inc. (GANX) saw revenue decline by 100.0% over the past year.
Gain Therapeutics, Inc. (GANX) reported a net loss of $19.4M for fiscal year 2024.
Dividend & Returns
Gain Therapeutics, Inc. (GANX) has a return on equity (ROE) of -205.0%. Negative ROE indicates the company is unprofitable.
Gain Therapeutics, Inc. (GANX) had negative free cash flow of $17.3M in fiscal year 2024, likely due to heavy capital investments.
Explore More GANX
Gain Therapeutics, Inc. (GANX) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates